Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.

SR9009

Другие языки:

SR9009

Подписчиков: 0, рейтинг: 0

SR9009
Identifiers

IUPAC name ethyl-3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)pyrrolidine-1-carboxylate
CAS Number	1379686-30-2
PubChem CID	57394020
ChemSpider	28487410
UNII	X5DCA09N30
ChEMBL	ChEMBL1961796
Chemical and physical data
Formula	C₂₀H₂₄ClN₃O₄S
Molar mass	437.94026 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCOC(=O)N1CCC(C1)CN(CC2=CC=C(C=C2)Cl)CC3=CC=C(S3)[N+](=O)[O-]
InChI InChI=1S/C20H24ClN3O4S/c1-2-28-20(25)23-10-9-16(13-23)12-22(11-15-3-5-17 (21)6-4-15)14-18-7-8-19(29-18)24(26)27/h3-8,16H,2,9-14H2,1H3 Key:MMJJNHOIVCGAAP-UHFFFAOYSA-N

SR9009, also known as Stenabolic, is a research drug that was developed by professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA) with a half-maximum inhibitory concentration (IC₅₀) = 670 nM for Rev-ErbAα and IC₅₀ = 800 nM for Rev-ErbAβ.

Activation of Rev-ErbA-α by SR9009 in mice increases exercise capacity by increasing mitochondria counts in skeletal muscle.

Abuse of SR9009 has been reported within the bodybuilding community, resulting in SR9009 being placed on the World Anti-Doping Agency list of prohibited drugs. SR9009 and the related SR9011 drug are described as "Hormone and Metabolic Modulators".

SR9009

See also